Syndax Pharmaceuticals stock hits 52-week low at 12.98 USD

Syndax Pharmaceuticals' stock has plummeted to a 52-week low of $12.98, suffering a nearly 20% decline in just one week. This represents an 8.53% drop over the past year, highlighting the significant challenges the company is encountering within the competitive pharmaceutical sector. Despite this bleak outlook, InvestingPro data suggests the stock may be undervalued, offering potential upside for patient investors.

The recent failure of the Phase 2 MAXPIRe trial for axatilimab in idiopathic pulmonary fibrosis has exacerbated the situation, prompting Syndax to suspend further development efforts in this area. However, the company's approved drug Niktimvo, used for chronic graft-versus-host disease, continues to show promise in upcoming trials.

Analysts have taken varying stances on Syndax, with Stifel and H.C. Wainwright maintaining Buy ratings and price targets around $40 and $38 respectively, expressing confidence in the potential of existing drugs. Conversely, Jefferies and UBS have also retained Buy ratings but have adjusted price targets downward, citing concerns about new patient starts for another product.

Overall, the mixed opinions among analysts reflect a cautiously optimistic sentiment, with investors closely monitoring Syndax's performance and upcoming data for clues to the company's future path.